Abstract: Benzodiazepine derivatives of formula (Ie) wherein one R1 and R2 is a benzodiazepinyl-containing group of formula (II) in which R8 is H or halo; the other of R1 and R2 is a group Z selected from H, C3-C6 cycloalkyl, halo, —NHR9, benzyl, phenyl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, wherein phenyl, heterocyclyl and heteroaryl are unsubstituted or substituted by one or two substituents selected from 4- to 10-membered heterocyclyl which is unsubstituted or substituted by OR, and from C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, halo, —OR, —(CH2)mOR, —NR2, —(CH2)mNR2, —NHR?, —SOmNR2, —SOmR, —SR, nitro, —CO2R, —CN, —CONR2, —NHCOR, —CH2NR10R11 and —NR10R11, in which each R is independently H or C1-C6 alkyl, R? is C3-C6 cycloalkyl and m is 1 or 2; R9 is selected from phenyl and 4- to 10-membered heteroaryl wherein phenyl and heteroaryl are unsubstituted or substituted by halo; R10 and R11 are each independently H or C1-C6 alkyl; or R10 and R11 form, together with the

Abstract: A system for managing a financial account in a low cash mode. The system may include a memory storing instructions, and a processor configured to execute the instructions to perform operations. The operations may include providing an interface; providing a notification to a user when a balance in the first account is deemed to be in low cash mode; presenting, when the first account balance is deemed to be in low cash mode, an option for a transfer request; receiving, a selection of the option for the transfer request to connect the first account with a second account; transferring funds from the second account to the first account; notifying the user that funds have been transferred from the second account to the first account; and further notifying the user that the balance in the first account is greater than the threshold value.

Abstract: A system for managing a financial account in a low cash mode. The system may include a memory storing instructions, and a processor configured to execute the instructions to perform operations. The operations may include providing an interface; providing a notification to a user when a balance in the first account is deemed to be in low cash mode; presenting, when the first account balance is deemed to be in low cash mode, an option for a transfer request; receiving, a selection of the option for the transfer request to connect the first account with a second account; transferring funds from the second account to the first account; notifying the user that funds have been transferred from the second account to the first account; and further notifying the user that the balance in the first account is greater than the threshold value.

Abstract: Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; R3 is H, C1-C6 alkyl or —NHR8; either (i), a, c and c are all bonds, with, b, d and f absent; or b, d, and f are all bonds, with a, c, and c absent; R4 is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R5 is H or halo; R6 is —OR8, —NR8R9 or —R8; R7 is H or halo; each of R8 and R9 is independently H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; n is 1 or 2; and one of V, W and X is N or CH and the other two are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

Abstract: A system for managing a financial account in a low cash mode. The system may include a memory storing instructions, and a processor configured to execute the instructions to perform operations. The operations may include providing an interface; providing a notification to a user when a balance in the first account is deemed to be in low cash mode; presenting, when the first account balance is deemed to be in low cash mode, an option for a transfer request; receiving, a selection of the option for the transfer request to connect the first account with a second account; transferring funds from the second account to the first account; notifying the user that funds have been transferred from the second account to the first account; and further notifying the user that the balance in the first account is greater than the threshold value.

Abstract: A system for managing a financial account in a low cash mode. The system may include a memory storing instructions, and a processor configured to execute the instructions to perform operations. The operations may include providing an interface; providing a notification to a user when a balance in the first account is deemed to be in low cash mode; presenting, when the first account balance is deemed to be in low cash mode, an option for a transfer request; receiving, a selection of the option for the transfer request to connect the first account with a second account; transferring funds from the second account to the first account; notifying the user that funds have been transferred from the second account to the first account; and further notifying the user that the balance in the first account is greater than the threshold value.

Abstract: Provided herein are stretch devices and related methods for controlled three-dimensional stretching of scaffolds supported on a stretchable substrate. A stretchable substrate is capable of receiving the three-dimensional scaffold, and a stretchable substrate holder is configured to connect to the stretchable substrate. An actuator is connected to the stretchable substrate holder to exert a cyclic stretch on the stretchable substrate and periodically stretch the three-dimensional scaffold connected to the stretchable substrate. A sample holder is configured to immerse the three-dimensional scaffold in a tissue culture media.

Abstract: Provided herein are self-collection devices for collecting and/or processing biofluids. The biofluid, such as saliva, is collected in a collection tube. A tube insert in the collection tube is configured to work with a cap having an integrated reservoir volume holding a reagent. Upon connecting the cap to the collection tube, the material in the reservoir volume is effectively introduced to or mixed with the sample in the collection tube. In this manner, there is no risk of user exposure to the reagent and no adverse impact on the ability to reliably mix reagent with sample. The device can then be shipped to a testing facility. Alternatively, a biomarker detection membrane may be used to detect more immediately, without shipping, presence or absence of a material in the sample. This provides for an almost instantaneous read-out that is incorporated into the self-collection device.

Abstract: The system and method of the present application improve pipeline integrity and may optimize operational efficiencies. Using the data that is generated by cathodic protection and pipeline integrity monitoring devices (e.g. rectifier monitoring), the present application utilizes data analytics techniques, such as artificial intelligence and machine learning algorithms, to improve pipeline integrity operations.

Abstract: Pharmacuetical Compounds Benzodiazepine derivatives of formula (I): wherein: R1 is H or F; R2 is selected from formula (II) and formula (III) R3 is C1-C6 alkyl which is unsubstituted or substituted by CF3, or is a monocyclic 4- to 6-membered heterocyclic group containing 1 or 2 heteroatoms selected from O, N and S; R4 is H or a group selected from —X, -alk-X, —CONR6R7, C?NNR6R7, —SO2R6 and —SO2NR6R7; R4 is a group selected from —X, -alk-X, —CONR6R7, —C?NNR6R7, —SO2R6 and —SO2R6R7; X is OH or a derivative of an OH group selected from ?-amino carboxylic acid esters, carboxylic acid esters, carbonates, carbamates, ethers and phosphates: alk is C1-C6 alkylene which is unsubstituted or substituted by C3-C6 cycloalkyl; and R6 and R7 are each independently C1-C6 alkyl or C3-C6 cycloalkyl; and the pharmaceutically acceptable salts thereof are inhibitors of respiratory syncytial virus (RSV) and can therefore be used to treat or prevent an RSV infection.

Abstract: Benzodiazepine derivatives of formula (Ib) wherein: R1 is H or halo; Y is selected from O, S, SO, SO2 and NR; one or two of V, W and X is or are N or CH and the other one or two is or are CH; R2 is a group selected from C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, halo, —OR, —NHR?, —SOmNR2, —SOmR, nitro, —CO2R, —CN, —CONR2, —NHCOR and —NR11R12; each R is independently H or C1-C6 alkyl; R11 and R12 are each independently H or C1-C6 alkyl; or R11 and R12 form, together with the N atom to which they are attached, either (a) a morpholine ring which is optionally bridged by a —CH2— group linking two ring carbon atoms that are positioned para to each other, or (b) a spiro group of the following formula (b): R? is C3-C6 cycloalkyl; m is 1 or 2; n is 0, 1 or 2; and each of R3 to R10 is independently selected from H, C1-C6 alkyl, halo, —OR, -NR2,—NHR?, —SOmNR2, —SOmR, nitro, —CO2R, —CN, —CONR2, —NHCOR, —NR13R 4 whereinR13 and R14 form, together with the N atom to which they are attached, a morpholine ring, and th

Abstract: Benzodiazepine derivatives of formula (Ie) wherein one R1 and R2 is a benzodiazepinyl-containing group of formula (II) in which R8 is H or halo; the other of R1 and R2 is a group Z selected from H, C3-C6 cycloalkyl, halo, —NHR9, benzyl, phenyl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, wherein phenyl, heterocyclyl and heteroaryl are unsubstituted or substituted by one or two substituents selected from 4- to 10-membered heterocyclyl which is unsubstituted or substituted by OR, and from C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, halo, —OR, —(CH2)mOR, —NR2, —(CH2)mNR2, —NHR?, —SOmNR2, —SOmR, —SR, nitro, —CO2R, —CN, —CONR2, —NHCOR, —CH2NR10R11 and —NR10R11, in which each R is independently H or C1-C6 alkyl, R? is C3-C6 cycloalkyl and m is 1 or 2; R9 is selected from phenyl and 4- to 10-membered heteroaryl wherein phenyl and heteroaryl are unsubstituted or substituted by halo; R10 and R11 are each independently H or C1-C6 alkyl; or R10 and R11 form, together with the

Abstract: Benzodiazepine derivatives of formula (I): wherein: each of R1 and R2 is independently H or halo; R3 is H, C1-C6 alkyl, —NHR8 or —OR?; either (i) a, c, and e are all bonds, with b, d and f absent; orb, d and f are all bonds, with a, c and e absent; R4 is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R5 is H or halo; R6 is —OR8, —NR8R9 or —R8; R7 is H or halo; each of R8 and R9 is independently H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R? is H or C1-C6 alkyl; and one of V and W is CH and the other is N or CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

Abstract: Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; R3 is H, C1-C6 alkyl or —NHR8; either (i), a, c and c are all bonds, with, b, d and f absent; orb, d, and f are all bonds, with a, c, and c absent; R4 is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R5 is H or halo; R6 is —OR8, —NR8R9 or —R8; R7 is H or halo; each of R8 and R9 is independently H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; n is 1 or 2; and one of V, W and X is N or CH and the other two are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection

Abstract: A modular microfluidic device for simulating in vivo conditions of a biological system may include a first perfusion chamber having an inlet and an outlet, a second perfusion chamber having an inlet and an outlet, a well configured to hold one or more 3D structures of cultured biological cells. The well may be in fluid communication with the first and second perfusion chambers. A first porous membrane may be disposed between the first perfusion chamber and the well. A second porous membrane may be disposed between the second perfusion chamber and the well. The well may be configured to facilitate growth of cultured biological cells along all three dimensional axes, thereby providing or ensuring a more representative 3D structure of biological cells compared to conventional monolayer cultures.

Abstract: Provided herein is a microphysiological system that may be used in various cell culture applications and biological system studies, that facilitates co-culture, monitoring, and study of functional interactions among different types of cellular and biological materials under various environmental conditions. The system is configured for fast assembly and disassembly, thereby minimizing damage or contamination of the biological materials and environmental conditions inside the system. The system comprises a base, a lid, and a plurality of clamps that are connected to the base and the lid. The base has a recess surface for receiving cell culture support layers. The lid has a stepped surface configured to exert a contact force to a top layer of one or more cell culture support layers during use. The clamp involves an engagement mechanism that generates a contact force allowing for sealing of the cell culture support layers in a manner that minimizes leakage of fluids.

Abstract: Pyrimidine derivatives of formula (I) wherein: Z is a direct bond or —(CH2)n— wherein n is 1 or 2; one of X and Y is N, CH or CF, and the other of X and Y is CH; one of R1 and R2 is selected from —NHR, —NR2, —OR, —SR, —S(O)R, —S(O)2R and a group of the following formula (A) and the other of R1 and R2 is selected from —NHR?, —OH, —OR? and a group of the above formula (A); R is unsubstituted C1-C6 alkyl; R? is a group selected from C1-C6 alkyl, 5- to 12-membered aryl and C3-C6 cycloalkyl, which group is unsubstituted or substituted; W is —(CH2)m—, —CH2—O—CH2—, —CH2—S—CH2— or —CH2—S(O)2—CH2—; p is 1, q is an integer of 1-6 and V is N; or p is 1, q is 0 and V is CH; or p is 0, q is 0 and V is N; r is 0 or 1; and R3 is —(CH2)s—NH2 or —(CH2)s—OH wherein s is 0 or an integer of 1 to 4; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

Abstract: Provided herein is a microphysiological system that may be used in various cell culture applications and biological system studies, that facilitates co-culture, monitoring, and study of functional interactions among different types of cellular and biological materials under various environmental conditions. The system is configured for fast assembly and disassembly, thereby minimizing damage or contamination of the biological materials and environmental conditions inside the system. The system comprises a base, a lid, and a plurality of clamps that are connected to the base and the lid. The base has a recess surface for receiving cell culture support layers. The lid has a stepped surface configured to exert a contact force to a top layer of one or more cell culture support layers during use. The clamp involves an engagement mechanism that generates a contact force allowing for sealing of the cell culture support layers in a manner that minimizes leakage of fluids.

Abstract: Pyrimidine derivatives of formula (I) wherein: Z is a direct bond or —(CH2)n— wherein n is 1 or 2; one of X and Y is N, CH or CF, and the other of X and Y is CH; one of R1 and R2 is selected from —NHR, —NR2, —OR, —SR, —S(O)R, —S(O)2R and a group of the following formula (A) and the other of R1 and R2 is selected from —NHR?, —OH, —OR? and a group of the above formula (A); R is unsubstituted C1-C6 alkyl; R? is a group selected from C1-C6 alkyl, 5- to 12-membered aryl and C3-C6 cycloalkyl, which group is unsubstituted or substituted; W is —(CH2)m—, —CH2—O—CH2—, —CH2—S—CH2— or —CH2—S(O)2—CH2—; p is 1, q is an integer of 1-6 and V is N; or p is 1, q is 0 and V is CH; or p is 0, q is 0 and V is N; r is 0 or 1; and R3 is —(CH2)s—NH2 or —(CH2)s—OH wherein s is 0 or an integer of 1 to 4; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.